Treatment Options for Distal Rectal Cancer in the Era of Organ Preservation

被引:1
|
作者
Wang, Chen [1 ]
Liu, Xiaoliang [1 ]
Wang, Weiping [1 ]
Miao, Zheng [1 ]
Li, Xiaoyan [1 ]
Liu, Dingchao [1 ]
Hu, Ke [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Radiat Oncol, 1 Shuaifuyuan Wangfujing, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Distal rectal cancer; Organ preservation; Adjuvant radiotherapy; Adjuvant chemotherapy; Watch and wait; Radical radiotherapy; TRANSANAL ENDOSCOPIC MICROSURGERY; TOTAL MESORECTAL EXCISION; PATHOLOGICAL COMPLETE RESPONSE; CLINICAL COMPLETE RESPONDERS; LOCAL EXCISION; OPEN-LABEL; POSTOPERATIVE CHEMORADIOTHERAPY; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT TREATMENT; RADIATION-THERAPY;
D O I
10.1007/s11864-024-01194-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The introduction of total mesorectal excision into the radical surgery of rectal cancer has significantly improved the oncological outcome with longer survival and lower local recurrence. Traditional treatment modalities of distal rectal cancer, relying on radical surgery, while effective, take their own set of risks, including surgical complications, potential damage to the anus, and surrounding structure owing to the pursuit of thorough resection. The progress of operating methods as well as the integration of systemic therapies and radiotherapy into the peri-operative period, particularly the exciting clinical complete response of patients after neoadjuvant treatment, have paved the way for organ preservation strategy. The non-inferiority oncological outcome of "watch and wait" compared with radical surgery underscores the potential of organ preservation not only to control local recurrence but also to reduce the need for treatments followed by structure destruction, hopefully improving the long-term quality of life. Radical radiotherapy provides another treatment option for patients unwilling or unable to undergo surgery. Organ preservation points out the direction of treatment for distal rectal cancer, while additional researches are needed to answer remaining questions about its optimal use.
引用
收藏
页码:434 / 452
页数:19
相关论文
共 50 条
  • [41] Recent advances in rectal cancer treatment - are we on the right track?
    Glimelius, Bengt
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2024, 129
  • [42] Local Excision for organ preservation in early REctal cancer with No Adjuvant treatment (LORENA Trial): prospective observational study protocol
    Perez, Rodrigo Tovar
    Cerdan-Santacruz, Carlos
    Cano-Valderrama, Oscar
    Escovar, Fernando Jimenez
    Lorente, Blas Flor
    Perez, Rodrigo
    Garcia-Septiem, Javier
    CIRUGIA ESPANOLA, 2024, 102 (09): : 506 - 512
  • [43] New treatment strategies for non-metastatic rectal cancer
    Abdalla, S.
    Benoist, S.
    Lefevre, J. H.
    Penna, C.
    Brouquet, A.
    JOURNAL OF VISCERAL SURGERY, 2021, 158 (06) : 497 - 505
  • [44] Rectal Cancer Update: Which Treatment Effects Are the Least "Brutal"?
    Wojcieszynski, Andrzej P.
    Chuong, Michael D.
    Hawkins, Maria
    Jethwa, Krishan R.
    Kim, Hyun
    Raldow, Ann
    Sanford, Nina N.
    Olsen, Jeffrey R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : 1 - 7
  • [45] Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer
    Yu, Zhen
    Hao, Yuying
    Huang, Yuhua
    Ling, Ling
    Hu, Xigang
    Qiao, Simiao
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer
    Martens, Milou H.
    Maas, Monique
    Heijnen, Luc A.
    Lambregts, Doenja M. J.
    Leijtens, Jeroen W. A.
    Stassen, Laurents P. S.
    Breukink, Stephanie O.
    Hoff, Christiaan
    Belgers, Eric J.
    Melenhorst, Jarno
    Jansen, Rob
    Buijsen, Jeroen
    Hoofwijk, Ton G. M.
    Beets-Tan, Regina G. H.
    Beets, Geerard L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (12):
  • [47] Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial
    Verweij, Maaike E.
    Tanaka, Max D.
    Kensen, Chavelli M.
    van der Heide, Uulke A.
    Marijnen, Corrie A. M.
    Janssen, Tomas
    Vijlbrief, Tineke
    van Grevenstein, Wilhelmina M. U.
    Moons, Leon M. G.
    Koopman, Miriam
    Lacle, Miangela M.
    Braat, Manon N. G. J. A.
    Chalabi, Myriam
    Maas, Monique
    Huibregtse, Inge L.
    Snaebjornsson, Petur
    Grotenhuis, Brechtje A.
    Fijneman, Remond
    Consten, Esther
    Pronk, Apollo
    Smits, Anke B.
    Heikens, Joost T.
    Eijkelenkamp, Hidde
    Elias, Sjoerd G.
    Verkooijen, Helena M.
    Schoenmakers, Maartje M. C.
    Meijer, Gert J.
    Intven, Martijn
    Peters, Femke P.
    BMJ OPEN, 2023, 13 (06):
  • [48] High nodal positivity rates even in good clinical responders after chemoradiation of rectal cancer: is organ preservation feasible?
    Vallam, K. C.
    Engineer, R.
    Desouza, A.
    Patil, P.
    Saklani, A.
    COLORECTAL DISEASE, 2016, 18 (10) : 976 - 982
  • [49] The Landmark Series: Organ Preservation in Rectal Cancer—The Watch and Wait Strategy
    Rodrigo O. Perez
    Bruna B. Vailati
    Guilherme P. São Julião
    Fernanda Mazzucato
    Leonardo E. Corbi
    Annals of Surgical Oncology, 2025, 32 (7) : 4945 - 4956
  • [50] Organ Preservation in Patients with Rectal Cancer Treated with Total Neoadjuvant Therapy
    Jimenez-Rodriguez, Rosa M.
    Quezada-Diaz, Felipe
    Hameed, Irbaz
    Kalabin, Aleksandr
    Patil, Sujata
    Smith, J. Joshua
    Garcia-Aguilar, Julio
    DISEASES OF THE COLON & RECTUM, 2021, 64 (12) : 1463 - 1470